Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro

Japanese Journal of Clinical Oncology

Volumn 29, Issue 7, 1999, Pages 323-331

  Suzuki, Koichi ^a,b   Kazui, Teruhisa ^a   Yoshida, Masayuki ^a   Uno, Takeji ^a   Kobayashi, Toshihiko ^a   Kimura, Taizo ^a   Yoshida, Teruhiko ^b   Sugimura, Haruhiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

5 deoxyfluorouridine; Apoptosis; BAX; BCL 2; p53

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; DOXIFLURIDINE; FLOXURIDINE; MESSENGER RNA; ONCOPROTEIN; PRODRUG; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLOXURIDINE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PRODRUGS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033158319     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.7.323     Document Type: Article

References (47)

1. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 1987;5:354-64.
2. Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol 1987;5:1523-33.
3. Inoue K, Ogawa M, Inagaki J, Horikoshi N, Ikeda K, Nakada H, et al. A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. Gan to Kagaku Ryoho 1984;11:1832-7 (in Japanese).
4. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.
5. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
6. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
7. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
8. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994;9:1767-73.
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
10. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
11. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
12. Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 1997;42:173-81.
13. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
14. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
15. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3.
16. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993;262:1274-7.
17. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
18. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
19. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983;31:175-8.
20. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
21. Shchepotin IB, Soldatenkov V, Buras RR, Nauta RJ, Shabahang M, Evans SR. Apoptosis of human primary and metastatic colon adenocarcinoma cell lines in vitro induced by 5-fluorouracil, verapamil and hyperthermia. Anticancer Res 1994;14:1027-31.
22. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
23. Igarashi H, Sugimura H, Maruyama K, Kitayama Y, Ohta I, Suzuki M, et al. Alteration of immunoreactivity by hydrated autoclaving, microwave treatment and simple heating of paraffin-embedded tissue sections. Apmis 1994;102:295-307.
24. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, et al. Apoptosis-related factors p53, Bcl2 and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52.
25. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
26. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
27. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
28. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nature Med 1998;4:1329-33.
29. Johnston PG, Lenz HJ, Lcichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
30. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987;262:8235-41.
31. Wurzer JC, Tallarida RJ, Sirover MA. New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther 1994;269:39-43.
32. Okamoto S, Sakai M, Uchida J, Saito U. 5-Fluorouracil induces apoptotic cell death with G2 phase arrest in human breast cancer grafted in nude mice. Anticancer Res 1996;16:2699-704.
33. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-beta 1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997;72:356-61.
34. Huschtscha LI, Bartier WA, Ross CE, Taltersall MH. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996;73:54-60.
35. Ueda M, Kumagai K, Ueki K, Inoki C, Orino I, Ueki M. Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. Int J Cancer 1997;71:668-74.
36. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994;70:335-41.
37. Pritchard DM, Watson AJ, Rotten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997;94:1795-9.
38. Sharma R, Adam E, Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer 1997;76:1011-6.
39. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, et al. Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-9.
40. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
41. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
42. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
43. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16:3845-8.
44. Norberg T, Lennerstrand J, Inganas M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998;79:376-83.
45. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. p53 protein expression in gastrointestinal lymphomas. Oncology 1997;54:84-7.
46. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J, et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 1996;69:437-41.
47. Lee WY, Jin YT, Tzeng CC. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. Anticancer Res 1996;16:3007-12.